Leading the Way in Life Science Technologies

GEN Exclusives

More »

Nov. 1, Vol. 31, No. 19

      • Retooling SBIR Not That Easy
      • Alex Philippidis
      • The Small Business Innovation Research (SBIR) program has been surviving on the same $2 billion per year budget since its authorization ended in fiscal 2008 thanks to three years of temporary spending fixes. The program’s authorization is now set to ... more »
      • Solution Supplier Expands Offerings
      • Carol Potera
      • Qiagen was established in 1984 in Dusseldorf, Germany. The company initially focused on molecular biology with its Plasmid-Kit, which reduced plasmid preparation time from a few days to two hours. Then in 1996, it introduced the BioRobot 9600, a ben ... more »
      • Vaccine Market Revenue Growing
      • Bruce Carlson
      • Double-digit growth can’t last forever in any category, and it is likely that vaccines will prove to be no exception. Vaccines will grow and will continue to be a major focus of pharmaceutical concerns, but they will grow at a tamer pace. Kalorama ... more »
      • Volatility Rattles Biotechnology Sector
      • Eugene Rozelman
      • Several macroeconomic concerns came to the forefront in the third quarter of 2011. Standard & Poor’s strapped on its dancing shoes and did the downgrade mambo, lowering its long-term sovereign credit rating on the U.S. to AA+ from AAA. Consumer ... more »
      • Directing Cell-Signaling Research
      • Josh P. Roberts
      • It’s hard to imagine a biomedical field that’s not concerned with cell signaling. From immunologists studying GPCRs and neuroscientists investigating amyloid plaques, to cardiologists telling their patients to avoid caffeine, knowing what’s connecte ... more »
      • GEN's 30th Anniversary: Peptide Therapeutics
      • The Peptide Therapeutics Foundation recently reported that 131 peptide drug candidates were in development and 54 additional ones had been approved for marketing. The foundation went on to note that over the past 30 years, peptides have been widely ... more »
      • Gene Therapy Briefs
      • Genevolve Vision Diagnostics developed a noninvasive molecular diagnostic for all major forms of congenital color blindness, for use by ophthalmologists and optometrists. The test, marketed under the Eyedox™ brand, involves using a noninvasive buc ... more »
      • Green Chemistry Initiatives Take Shape
      • Gail Dutton
      • Many innovative companies are embracing green chemistry, citing environmental sustainability, increased efficiency, and lowered costs, as they develop the tools and measurements that inform the choices of solvents and reagents throughout a compound’ ... more »
      • Redefining High-Resolution Mass Spec
      • John Russell
      • Tradeoffs between resolution, sensitivity, and speed are inevitable in chemical analysis but strides are being taken to boost resolution and to improve “qual-quant” methods that enable researchers to identify and quantify compounds in a single workf ... more »
      • Regen Med Success Hinges on Engineering
      • Stuart Kay
      • As highlighted in the article “Engineering Regenerative Medicine’s Future” in the September 1, 2011 issue of GEN, there is international recognition among stakeholders in the regenerative medicine sector that the commercialization of novel therapeut ... more »
      • Gene Cloning and Colony Picking
      • Tamara Brown, Ph.D.
      • Colony picking is a very labor-intensive task that is generally performed during cloning protocols, alongside additional upstream and downstream processes. Manual colony picking is both slow and tedious. Automation makes the process more consistent ... more »

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »